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Secondary hyperparathyroidism (SHPT) remains a highly
prevalent and important complication in patients with
chronic kidney disease (CKD). Indeed, SHPT may compromise
bone health and contribute to the increased cardiovascular
risks of these patients. Calcimimetic agents may help to
control SHPT and to achieve the stringent mineral
metabolism targets in patients with CKD stage 5D. Whether
this will translate in improved patient-level outcomes
remains to be demonstrated in adequately powered
prospective intervention studies. These studies are currently
ongoing. Additional investigations are required to define
how calcimimetics fit best in the expanding armamentarium
to treat SHPT. The role of vitamin D (analogs) and
parathyroidectomy needs to be reevaluated in the
calcimimetic era. Persistent hyperparathyroidism after
successful renal transplantation may also become an
important indication for therapy with calcimimetics. In
patients with this complication, calcimimetics may help to
improve bone health both by suppressing bone turnover and
demineralization and may retard or prevent nephrocalcinosis
of the graft. The evidence for using calcimimetics in CKD
patients not yet on dialysis, conversely, is less
straightforward. In these patients, therapy for SHPT should
rather be focused on the primary trigger, i.e. the high
phosphate load relative to the functional nephron mass.
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Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease (CKD). SHPT is
generally associated with abnormally high rates of bone
resorption and is often accompanied by pain and fractures.1,2
Extraskeletal manifestations of the disease include vascular
calcification, hypertension, anemia, pruritus, and sexual
dysfunction.3–5 Epidemiological data demonstrate significant
relations among elevated parathyroid hormone (PTH),
calcium (Ca), and phosphorus (P) and mortality and
morbidity.6–10 Block et al.8 showed in a large hemodialysis
cohort that PTH concentrations 4600 pg/ml are associated
with an increase in the risk for death compared with PTH
concentrations o600 pg/ml; higher PTH was also associated
with higher risks for cardiovascular disease and fracture. In
the same analysis, hyperphosphatemia and hypercalcemia
were associated with mortality as well.8 It should be noted
that the PTH–mortality relation was weaker than the
phosphorus–mortality or calcium–mortality relations.
Guidelines from the National Kidney Foundation (NKF)
Kidney Disease Outcomes Quality Initiative (K/DOQI)
recognize the intimate relations between bone mineral
disease, vascular calcification, and mortality, and propose
stringent targets for serum PTH, calcium, and phosphorus.11
Unfortunately, the exact interplay between these biomarkers
is unknown and the relationship between combinations of
biomarkers and long-term clinical outcomes remains poorly
characterized.12
Treatment for SHPT should maintain a PTH concentra-
tion compatible with normal turnover of bone, prevent the
development of parathyroid hyperplasia, maintain physiolo-
gical concentrations of phosphorus and calcium, and be free
of any tendency to accelerate the development and progres-
sion of vascular and soft tissue calcification.
Besides dietary phosphate restrictions, phosphate-binding
agents and vitamin D sterols have been the cornerstone for
managing SHPT for a long time. With this treatment
regimen, however, K/DOQI targets are difficult to achieve
on a constant basis. One large study of hemodialysis patients
from seven countries found that only 21% of patients
satisfied the guidelines’ criteria for PTH concentration and
5% met combined targets for calcium, phosphorus, PTH,
and Ca P.9
In recent years, novel therapeutic agents such as calcium-
free phosphate binders and vitamin D analogs have become
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available that will facilitate control of hyperphosphatemia
and hyperparathyroidism while the calcium load is mini-
mized. Calcimimetics are the latest acquisition in the
expanding therapeutic armamentarium of SHPT.13 Calcimi-
metics allosterically modulate the Ca-sensing receptor
(CaSR), a G-protein-coupled receptor that is present on the
parathyroid gland, increasing its sensitivity to extracellular
Ca and thereby lowering PTH secretion from the parathyroid
gland.14,15 Calcimimetics also mediate reductions in serum
PTH levels by decreasing PTH gene expression.16 Finally,
recent data indicate that calcimimetics reduce PTH synthesis
also indirectly through increasing the vitamin D receptor
expression in the parathyroid glands.17
Cinacalcet HCl is at present the only commercially
available calcimimetic agent. It was approved by the United
States Food and Drug Administration in 2004 and by the
European Medicines Agency in 2005 for the treatment of
SHPT of dialysis patients and parathyroid carcinoma.
Manufactured by Amgen, cinacalcet HCl is marketed as
Sensipar (Amgen Inc., Thousand Oaks, CA, USA) in the US
and as Mimpara (Amgen Inc.) in Europe.
This review aims to summarize the available clinical
experience with calcimimetic therapy and to touch on future
opportunities and threats.
SHPT IN CKD STAGE 5D
Biochemical outcomes
In early studies, single doses of cinacalcet given to
hemodialysis patients simultaneously reduced PTH and
serum calcium.18 It is important to note that PTH levels
decreased already during the first hour after dosing to reach a
nadir (72% reduction in the 100 mg group) at approximately
4 h post-dose. PTH levels did not return to baseline in the
subsequent 28 h. Reductions in serum calcium followed a
similar pattern to those of PTH.18 In a small longitudinal
study in hemodialysis patients with uncontrolled SHPT, PTH
increased by 3% in the placebo group and fell by 33% in
the cinacalcet group; Ca P rose by more than 11% in the
placebo-treated patients but fell by almost 8% in the
treatment group.19 A similar picture has emerged from
subsequent larger studies with longer follow-up. In 741
patients treated for 26 weeks, there was a 30% reduction in
PTH from baseline values in two-thirds of cinacalcet-treated
patients, compared with in 11% of those receiving standard
care. Ca P was unchanged with standard care, but fell 15%
in the treatment arm. The likelihood of achieving a PTH level
of p250 pg/ml was independent of gender, race, age,
duration of dialysis, baseline biochemical variables, the
presence of diabetes, or the use of vitamin D sterols.20 The
differential response among those who received cinacalcet
may point to genetic influences. These remain to be explored.
The mechanism underlying the declines of calcium and
phosphorus remains incompletely understood. In the absence
of substantial residual renal function, alterations in the
exchange of these minerals between extracellular fluid and
the miscible pool in bone are most likely responsible. Studies
in parathyroidectomized and/or thyroidectomized rats clearly
indicate that the calcimimetic NPS R-568 induces hypocal-
cemia not only by inhibiting PTH secretion but also by
stimulating calcitonin secretion.15 This dual action may
explain the different kinetics of serum calcium levels after
parathyroidectomy and cinacalcet administration. Finally,
functioning CaSRs within the skeleton could potentially play
a role as well.
With respect to the changes in serum calcium and
phosphorus, calcimimetic agents differ from calcium-contain-
ing phosphate binders (which raise calcium and lower
phosphorus and PTH) and vitamin D compounds (which
raise calcium and phosphorus and lower PTH). Obviously,
cinacalcet facilitates the achievement of the K/DOQI-recom-
mended targets for PTH, calcium, phosphorus, and Ca P in
CKD stage 5D.21,22 Recent data show that cinacalcet can
effectively maintain reductions in PTH for up to 3 years,
without increasing concentrations of serum calcium and
phosphorus and without any attenuation.23 Recent clinical
research mainly focuses on strategies for optimization of the
management of SHPT with cinacalcet. Chertow et al.24
demonstrated that control of PTH levels was maintained by
substituting active vitamin D by cinacalcet. Moreover, the
introduction of cinacalcet significantly improved control of
Ca P, resulting in an increase in the proportion of patients
who simultaneously achieved the PTH and Ca P target levels
(17–47% during the course of the study). In Europe, two post-
registrational studies including a total of more than 1200
dialysis patients have been conducted to investigate strategies
for optimization of the management of SHPT with cinacalcet.
In the recently completed OPTIMA phase IIIB trial, a new
cinacalcet-based treatment algorithm that allowed for reduc-
tions in vitamin D dose was demonstrated to increase the
achievement of K/DOQI treatment targets in dialysis patients
in whom conventional therapy was no longer effective.25 In the
SENSOR phase IIIB trial, patients were randomized to
cinacalcet intake during dialysis or with the first major meal
after dialysis. The same cinacalcet-based treatment algorithm
as in the OPTIMA trial is applied to optimize cinacalcet,
vitamin D, and phosphate binder use.26 Results of the latter
trial are expected in the near future.
Clinical outcomes
The aforementioned trials provide convincing evidence that
the introduction of calcimimetic drugs represents a real
opportunity to improve the paradigm of managing the
biochemical variables associated with SHPT. While the
effective treatment of hypercalcemia and SHPT is of clinical
interest, it remains to be demonstrated whether this will
translate into improvement in hard end points such as bone
health or cardiovascular morbidity and mortality.
Calcimimetics and bone health. Epidemiological data have
clearly demonstrated an increased fracture risk in hemodia-
lysis patients.1,27 Two main mechanisms may account for the
increased fracture risk: either a lower resistance of bone after
relative minor traumas or an increased propensity to fall.28
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Renal osteodystrophy, being a prevalent complication of CKD,
accounts to a large extent for a lower resistance of bone in
hemodialysis patients. Renal osteodystrophy comprises a
number of histologically distinct bone abnormalities that are
generally classified as either high-turnover (osteitis fibrosa,
mild, and mixed) or low-turnover (osteomalacia and ady-
namic) lesion. So far, the utility of biochemical markers of bone
turnover to predict the type of skeletal lesions is disappointing.
A bone biopsy with dynamic tetracycline labeling remains the
‘gold standard’ to evaluate bone health in humans.
In the presence of elevated PTH concentrations, hyper-
parathyroid bone disease (osteitis fibrosa) most typically
develops. Treatment with the calcimimetic agent NPS R-568
has been shown in uremic rats to reduce serum PTH levels, to
eliminate osteitis fibrosa, and to return cortical bone strength
toward normal.29
Over the past decade, the prevalence of different forms of
renal osteodystrophy has shifted. Whereas hyperparathyroid
bone disease was the most common abnormality observed in
the 1980s, the prevalence of adynamic bone disease has risen
over the past decade.30 The reported prevalence of low bone
turnover varies from 5 to 61%.31–33 Diabetes, the adminis-
tration of pharmacologic doses of vitamin D sterol, and large
doses of calcium-containing phosphate binders have been
implicated in the pathogenesis of adynamic bone disease.34–36
The clinical relevance of adynamic bone remains controver-
sial. Nevertheless, several lines of evidence indicate a link with
increased fracture risk and with accelerated cardiovascular
calcification.37–39 Animal studies indicate that cinacalcet
might play a role in the treatment of this entity as well. In
rats exhibiting a low-turnover bone lesion resembling
osteomalacia despite the presence of mild SHPT, NPS R-
568 had an ‘anabolic-like’ action when administered by daily
gavage. It is speculated that intermittent decreases in the
serum level of PTH are sufficient to reverse the phenomenon
known as ‘homologous receptor desensitization’; that is,
prolonged exposure to PTH in itself may cause the
desensitization of the PTH receptors.40 Miller and Fox41
showed that daily transient decreases in PTH levels induced
by NPS R-568 slow the rate of bone loss but do not increase
bone mass in ovariectomized rats with normal PTH. Elevated
serum levels of PTH before treatment, therefore seem critical
for stimulating bone formation. In some respects, the
findings by Ishii et al.40 parallel those obtained when the
serum levels of PTH are increased intermittently.42,43
Clinical data on the impact of calcimimetics on bone
mineral density and on bone histomorphometry are limited.
A small placebo-controlled 1-year repeat bone biopsy study
in 32 hemodialysis patients with SHPT showed favorable
trends in bone turnover and fibrosis in the cinacalcet-treated
subjects but failed to show significance most probably due to
lack of power.44 Moreover, preliminary clinical data suggest a
beneficial effect on bone mineral density in patients with
SHPT treated with cinacalcet.45
The ongoing Bone Histomorphometry Assessment For
Dialysis Patients with Secondary Hyperparathyroidism of
End Stage Renal Disease (BONAFIDE study) will give a
definite answer to the question whether cinacalcet has a
beneficial effect on bone health in patients with CKD 5D and
established hyperparathyroid bone disease. The primary end
point of this multicenter, uncontrolled, descriptive bone
biopsy study is the change from baseline in bone formation
rate. Eighty-five subjects are scheduled for inclusion. Results
of this study are to be expected by 2009.
Even if the outcome of the BONAFIDE study is favorable
for cinacalcet treatment, it remains to be seen whether this
treatment will result in a decreased fracture risk. The recent
post hoc analysis of all randomized controlled trials of
cinacalcet versus placebo (in both arms with standard
treatment of SHPT) showed a significantly lower actuarial
risk of fracture in the cinacalcet group (relative risk 0.46, 95%
CI 0.22–0.95).46 This post hoc analysis requires confirmation
by randomized trials, including fractures in the pre-defined
major end points.
Modification of calcification and other cardiovascular risk
factors by calcimimetics
Cardiovascular calcification. Both in uremic and in non-
uremic individuals, the extent and the progression of
cardiovascular calcification increase the risk for cardiovas-
cular morbidity and mortality.47–50 Although the causes of
vascular calcification in CKD remain to be elucidated,
abnormalities in mineral metabolism are increasingly recog-
nized to play an important role.51–54 In this regard, the close
relationship between bone disease and vascular calcification
should be acknowledged.37,55,56 Oversuppression of PTH and
calcium loading, for example, due to the overzealous use of
calcium-containing phosphate binders or vitamin D analogs,
have been associated with accelerated cardiovascular calcifi-
cation in several studies.54,57 Calcimimetics, conversely, have
been shown to reduce elevated PTH levels without inducing
vascular calcification and to prevent calcitriol-induced
vascular calcifications.58,59 The mechanisms of action that
are responsible for the anticalcification effect of the
calcimimetics are poorly understood. Both an indirect effect
through control of PTH levels without increasing the Ca P
product and a direct effect at the cellular level on the arterial
vessel wall are plausible.
In a recent uncontrolled clinical trial in hemodialysis
patients, Messa et al.60 observed increased osteoprotegerin
and decreased fetuin-A levels following the initiation of
cinacalcet treatment. This is an important observation as
both fetuin-A and osteoprotegerin are acknowledged to be
key factors in the pathogenesis of vascular calcification in
CKD.61 The changes reported by Messa et al. confer an
increased risk of vascular calcification.62,63 Alternatively these
changes reflect a reduced demand for feedback defense
mechanisms, which may be secondary to improved mineral
metabolism. This hypothesis was proposed by Mehrotra
et al.64 to explain observations made in non-dialysed diabetic
nephropathy patients. Undoubtedly, additional controlled
(longitudinal) trials are needed for clarification.
Kidney International (2008) 74, 265–275 267
P Evenepoel: Calcimimetics in CKD t r a n s l a t i o n a l n e p h r o l o g y
Hypertension and dyslipidemia. Hypertension and dyslipi-
demia are prevalent in renal failure and contribute to the
increased cardiovascular risk. In experimental renal failure,
abrogation of SHPT by administration of a calcimimetic
mitigates the development of hypertension, dyslipidemia,
and cardiac remodeling.65,66 Similar changes have been
reported after parathyroidectomy both in animals and
patients.65,67 The underlying pathophysiological mechanisms
are only poorly understood.
Calcimimetics may result in reduced peripheral vascular
resistance either directly via activation of the CaSR or
indirectly by the decrease of ionized calcium. Alternatively,
the blood pressure-lowering effect may be mediated via
suppression of the PTH serum levels.66,68,69 Clinical studies
with calcimimetic agents available so far have not been
designed to evaluate effects on blood pressure, and none of
the published trials has reported any impact on blood
pressure.18,20,70
Decreased activity of both lipoprotein71 and hepatic72
lipase has been implicated in the pathogenesis of dyslipide-
mia related to hyperparathyroidism. These changes in lipase
metabolism were corrected by parathyroidectomy (PTX)71,72
and calcium channel blockade.72 The latter supports a
causative role of cytosolic calcium concentrations. The
observation that administration of insulin corrected the
disturbed metabolism of triglyceride-rich particles indicates
that the effect of PTH at least partially involves inhibition of
insulin secretion or interference with its peripheral action.73
Cardiovascular morbidity and mortality
It is well recognized that cardiovascular morbidity and
mortality in patients with CKD is a problem of epidemic
proportion. The abovementioned data suggest that calcimi-
metics may beneficially modify several risk factors and thus
improve cardiovascular outcomes in CKD stage 5D. Data
from a post hoc analysis showing a significant reduction in
hospitalization for cardiovascular disease and a trend toward
improved mortality among patients who were randomly
assigned to cinacalcet versus placebo corroborate this
hypothesis.46 The ongoing Evaluation of Cinacalcet Therapy
to Lower cardiovascular Events (EVOLVE) trial is designed to
prospectively test the hypothesis that cinacalcet improves
cardiovascular outcomes in hemodialysis patients. Approxi-
mately 3800 CKD stage 5D patients from 22 countries will be
randomly assigned to cinacalcet or placebo. Flexible use of
traditional therapies is permitted. The study is event driven,
with an anticipated duration of approximately 4 years.74
Whether the EVOLVE trial will come to the high expectations
of the nephrology community remains to be seen. Prudence
is justified. Indeed, prior large randomized intervention trials
in CKD stage 5D, including those on lipid reduction,75
normalization of hematocrit,76 and increased dialysis
dosage,77 and the recent Dialysis Clinical Outcomes Revisited
(DCOR) trial78 failed to show a benefit despite the wealth of
available evidence in favor of the intervention at the time of
conception of these studies.
SHPT IN PATIENTS WITH CKD NOT YET ON DIALYSIS
NKF-K/DOQI guidelines recognize that early treatment of
SHPT in patients with CKD not receiving dialysis is likely to
improve long-term outcomes and reduce disease severity.11
The complexity of hyperparathyroidism physiopathology
is well recognized. Recent clinical studies demonstrate a high
fractional phosphate excretion along with elevated PTH and
fibroblast growth factor 23 (FGF-23) levels in patients with
early CKD despite the presence of normophosphatemia.79–81
These findings indicate that in progressive renal failure
compensatory increases in renal phosphate excretion are
recruited before the development of hyperphosphatemia.
This increase in renal phosphate excretion is driven, at least
partly by PTH and FGF-23, a recently discovered important
phosphaturic hormone.80,82–84 Renal 1-a-hydroxylase activity
is impaired by FGF-23 leading to decreased calcitriol
synthesis and reduced calcitriol levels.85 Inadequate calcitriol
synthesis provides a physiological explanation for impair-
ments in intestinal calcium absorption and for the hypo-
calciuria and modest hypocalcemia that characterize
untreated patients with moderate renal insufficiency.86–88
Inadequate calcium absorption prompts adaptive responses
by the parathyroid glands to maintain blood ionized calcium
concentrations.89 Overall, the well-known 25-year-old trade-
off theory, according to which hyperparathyroidism is the
price to pay for preventing hyperphosphatemia and hypo-
calcemia, seems to remain valid.90
In a recent study in patients with CKD not yet on dialysis,
the addition of cinacalcet significantly decreased PTH levels
compared to controls.91 The observed reductions in PTH
levels were similar to those observed in dialysis patients
treated with cinacalcet. In addition, the 24-h phosphaturia
decreased, whereas serum phosphorus concentrations in-
creased (4.0 to 5.0 mg per 100 ml, Po0.05) in the cinacalcet-
treated patients. This observation was not unexpected given
the phosphaturic effects of PTH, but contrasts to what is seen
in hemodialysis patients (Table 1). The long-term impact of
these biochemical changes on relevant outcome variables
such as progression of renal disease and cardiovascular
morbidity and mortality remains to be investigated.
In several animal studies, suppression of PTH levels has
been shown to attenuate the progression of renal failure.65,93
This beneficial effect on progression may be mediated by
hemodynamic changes induced by PTH.94 Alternatively,
suppression of PTH may prevent or retard nephrocalcinosis.
The ‘calcification–precipitation’ hypothesis proposes that
Table 1 | Effects of cinacalcet on parameters of mineral
metabolism in CKD patients
CKD stage 5D CKD 3–5 (T) Reference
Serum calcium k k 20,91,92
Serum phosphorus k m 20,91,92
PTH k k 20,91,92
Bone-specific AP k m 44,92
FEPO4 — k
92
AP, alkaline phosphatase; FE, urinary fractional excretion; PTH, parathyroid hormone.
268 Kidney International (2008) 74, 265–275
t r a n s l a t i o n a l n e p h r o l o g y P Evenepoel: Calcimimetics in CKD
phosphate absorbed in excess of residual nephron excretory
capacity produces precipitation and deposition of calcium
phosphate microcrystals in the tubular lumen, peritubular
space, capillaries, and interstitium and is thus responsible for
progressive functional deterioration in CKD.95,96 Suppression
of PTH by calcimimetics may cause the tubular phosphate
concentrations to drop below a critical threshold and thereby
may prevent precipitation to occur. At least in furosemide-
treated young rats, NPS R-467 has been shown to prevent the
development of hyperparathyroidism and to attenuate
nephrocalcinosis.97 Additional animal and/or clinical renal
biopsy studies are required to clarify whether, and if so to
what extent calcimimetics prevent nephrocalcinosis and
progression of renal disease.
As in patients with CKD stage 5D, high levels of serum
phosphate have been associated with increased cardiovascular
morbidity and mortality in predialysis patients.98–100 For
example, in the recent PREPARE study, a prospective
observational cohort study conducted in The Netherlands,
a 62% increase in mortality for each milligram per 100
milliliter increase in plasma phosphate concentration was
observed independent of age, gender, primary kidney disease,
baseline estimated glomerular filtration rate, and comorbid-
ity at baseline.100 It should be acknowledged that the design
of these studies does not allow conclusions on causality.
Nevertheless, recent findings in Klotho-knockout mice
corroborate the association between hyperphosphatemia
and cardiovascular morbidity and mortality. Klotho converts
canonical FGF receptor into a specific receptor for FGF-23.
When Klotho-knockout mice are fed a phosphate-containing
diet, these mice develop severe hyperphosphatemia101 and
cardiovascular calcification similar to those seen in dialysis
patients.102 When phosphate is restricted from the diet,
Klotho-knockout mice develop normally, which confirms an
important role of phosphate in increased cardiovascular
mortality in (early) CKD patients.103
In summary, the rationale for using calcimimetics for the
treatment of SHPT in CKD patients not yet on dialysis is
obviously less clear than it is in dialysis patients.
PERSISTENT HYPERPARATHYROIDISM AFTER SUCCESSFUL
RENAL TRANSPLANTATION
Successful kidney transplantation corrects the endocrine and
metabolic imbalances and the main abnormalities responsible
for SHPT in the first months.104–106 PTH levels show a
biphasic decline after successful renal transplantation: a rapid
drop (by approximately 50%) during the first 3–6 months,
attributed to a reduction of the parathyroid functional
mass,105 followed by a more gradual decline.107 The long
lifespan of parathyroid cells (approximately 20 years) with a
cell renewal rate of approximately 5% per year contributes to
the very slow involution of the gland after renal transplanta-
tion.108 As a result, elevated intact PTH levels are observed in
more than 25% of patients 1 year after successful renal
transplantation.107,109 Substantial evidence indicates that
persistent hyperparathyroidism is implicated in the patho-
genesis of post-transplant hypercalcemia, hypophosphatemia,
and most probably also bone disease.110–113 Furthermore,
recent data indicate that persistent hyperparathyroidism may
be involved in the pathogenesis of nephrocalcinosis of the
renal transplant, which, in turn, is independently associated
with chronic allograft nephropathy.114
Data from several small series indicate that cinacalcet is an
effective agent for the treatment of hypercalcemia secondary
to persistent hyperparathyroidism in renal transplant reci-
pients.92,115–120 The mechanism of calcium reduction is most
probably a decrease in the PTH effect on the bone. A
decreased tubular reabsorption as a result of lower PTH levels
and/or a direct effect of the calcimimetic on the CaSR in the
kidney is unlikely to play a relevant role as enhanced calciuria
is not universally observed in patients or animals following
treatment with calcimimetics.92,121 Cessation of the calcimi-
metic therapy results in the return of serum calcium and
PTH levels to pretreatment values in most transplant
patients.115,117
Overall the drug is well tolerated. Some groups, however,
observed a limited but significant drop of the glomerular
filtration rate following the initiation of cinacalcet. Especially
the cyclosporine-treated patients seem to be at risk for renal
function deterioration.122 Renal function restores after
cessation of the calcimimetic.115 This suggests a hemody-
namic rather than a structural mechanism. Renal function
deteriorations have also been described in the first weeks
following parathyroidectomy.67,123 It is important to note
that in the long-term a parathyroidectomy had no detri-
mental effect on graft outcome.124
Although cinacalcet interacts with CYP1A2, 2D6, 3A4
when metabolized and inhibits CYP2D6, clinically relevant
interactions with the standard immunosuppressive drugs
cyclosporine, tacrolimus, sirolimus, and everolimus have not
been reported.92,122,125
Appropriately designed and powered clinical trials,
examining the impact of calcimimetics on hard end points
or relevant surrogate markers, such as bone mineral density,
cardiovascular calcification or nephrocalcinosis, are required
to further define the role of this novel class of drug in the
treatment of persistent hyperparathyroidism after successful
renal transplantation.
CALCIMIMETICS AND PARATHYROID GLAND SIZE
It is well known that parathyroid enlargement due to
parathyroid cell proliferation (hyperplasia) is a major
determinant of PTH hypersecretion.89,108 An important
question that remains to be answered is whether calcimi-
metics affect gland size and if so, at what rate?126 Wada
et al.127 performed short- and long-term studies in rats with
chronic renal failure and showed that the oral administration
of the calcimimetic NPS R-568 prevented excessive para-
thyroid cell proliferation and gland hyperplasia, when given
at the time of renal mass reduction. Recent data confirm and
extend these observations.128–130 Colloton et al.128 demon-
strated that that orally administered cinacalcet arrested
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parathyroid cell proliferation in rats with established chronic
renal failure and even induced the regression of parathyroid
hyperplasia. The drug was given to animals for 4 weeks,
starting 6 weeks after the surgical induction of uremia. This
study was the first to demonstrate regression of parathyroid
gland volume in a uremic rat model within a relatively short
time period. Very recently, Mizobuchi et al.130 demonstrated
that high concentrations of the calcimimetic compound
R-568 accelerate the apoptosis of parathyroid cells from
uremic rats in vitro.
Clinical studies are urgently needed to confirm these
animal studies. Such studies are hampered by the lack of an
accurate, reliable method for measuring the parathyroid
gland size.89 A few studies have established a relationship
between functional mass parameters derived from the iCa-
PTH suppression/stimulation test and the parathyroid gland
size evaluated by ultrasonography131 or measured at the time
of parathyroidectomy in transplant patients.132 The iCa-PTH
suppression/stimulation test is currently the best tool
available to evaluate the parathyroid functional mass.105
TOXICITY/SIDE EFFECTS
Several studies have shown that long-term treatment with
cinacalcet is generally well tolerated. The two most common
adverse events are hypocalcemia and gastrointestinal side
effects. Hypocalcemia is considered to result from decreased
calcium mobilization from the bone under lowered PTH
conditions. This hypocalcemia was found to be generally
asymptomatic and could be readily managed by modest
adjustments to the dialysate calcium content or to the doses
of calcium-containing phosphate binders, vitamin D sterols,
or cinacalcet.20 These measures warrant caution as they
contribute to a positive calcium balance with potentially
harmful consequences in the long term.
Over the last two decades, the focus of attention in the
treatment of SHPT has shifted from the control of PTH levels
toward the prevention of cardiovascular calcification. As a
result of this paradigm shift, calcium-containing phosphate
binders, calcitriol supplements, and high calcium dialysate
baths (1.5–1.75 mmol/l) are increasingly replaced by non-
calcium-containing phosphate binders, novel vitamin D
analogs (presumed to be less calcemic), and low calcium
dialysate baths (1.25 mmol/l or less), respectively. These
changes in therapy may cause the serum calcium levels to
drop toward the lower end of the target range. Caution is
warranted when initiating calcimimetics in these patients.
One should indeed be aware that after administration of
cinacalcet, serum calcium levels follow a similar time course
to those of PTH, that is, a pronounced decrease reaching a
nadir at 4 h post-dose.18 When superimposed on an already
low baseline calcium level, temporary but severe hypocalce-
mia may occur, which may become clinically relevant
(malignant arrhythmia, cardiac failure) especially in cardio-
vascular vulnerable patients.133,134 Besides temporary hypo-
calcemia, prolonged hypocalcemia may also occur due to an
increased shift of calcium from the circulation to the bone
tissues.135,136 This condition which results from the transient
quantitative uncoupling between bone formation and
resorption137 is often encountered after parathyroidect-
omy138 and is often referred to as the ‘hungry bone
syndrome’.139
The mechanisms underlying the gastrointestinal side
effects are unclear. The CaSR is expressed on numerous
cell/tissue types present in the gastrointestinal tract. However,
no antiproliferative actions on intestinal epithelial cells were
observed in cinacalcet-treated animals.127 Interference with
the production/secretion of gastrointestinal hormones or the
gastrointestinal transit represents alternative explanations.
Further basic and clinical investigations are required to clarify
the pathophysiological mechanisms underlying the gastro-
intestinal side effects.
PHARMACOKINETICS
The calcimimetic agent NPS R-568 was efficacious in primary
and SHPT and in parathyroid carcinoma;15 however, the
unpredictable pharmacokinetics of this compound led to its
replacement by cinacalcet hydrochloride. The metabolism
and disposition of cinacalcet have been examined in
experimental animals and human volunteers.140 In patients
on dialysis, a once daily administration is appropriate.141
Changes in plasma PTH levels correlated inversely with
changes in cinacalcet levels. Importantly, the pharmacoki-
netic properties of cinacalcet after a single administration are
not influenced by the hemodialysis procedure.142 Pharmaco-
kinetic studies suggest that shorter dosing intervals should be
advised in patients with preserved renal function.143
THERAPY WITH CALCIMIMETICS VERSUS PTX
Therapy with cinacalcet may be considered an alternative for
parathyroidectomy in patients with severe SHPT. In fact,
therapy with calcimimetics is often referred to as a ‘reversible
chemical parathyroidectomy’.
Biochemical parameters of mineral metabolism show
comparable changes after PTX144,145 and during therapy
with cinacalcet. The fact that hypoparathyroidism is less
likely to occur with cinacalcet treatment than with PTX may
be considered an advantage of the medical approach.
Whether iatrogenic hypoparathyroidism will inevitably result
in adynamic bone disease remains to be demonstrated.
Studies addressing this issue are scanty and, overall, have
yielded conflicting results.146–151 Hampl et al., for example,
provided evidence that even 20 years after total PTX a normal
bone metabolism can be maintained in hemodialysis patients
by adequate substitution with oral calcium and vitamin D
supplements despite almost undetectable PTH levels. In
addition, several surgical case studies have reported an
increase in bone mineral density after PTX.152 These data,
together with the recent observation of a lower fracture risk
among hemodialysis patients who underwent PTX compared
with matched controls, suggest that the amelioration of
biochemical consequences of SHPT by PTX may outweigh
potential risks of long-term hypoparathyroidism at least in
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terms of bone health.153 In addition, several authors observed
a regression or stabilization of soft tissue calcification
following parathyroidectomy.146,154 Finally, data from the
United States Renal Data System and Dialysis Morbidity and
Mortality Study demonstrated that PTX is associated with
lower long-term mortality rates among US patients receiving
chronic dialysis.155,156
In the absence of prospective studies comparing outcomes
of cinacalcet plus standard therapy versus parathyroidectomy,
both approaches should be considered complementary rather
than competitive.157 Indeed, therapy with calcimimetics may
be the only option in high-risk patients and those unwilling
to undergo surgery. Calcimimetics may also be effective in
controlling relapses of SHPT after PTX.158 On the other
hand, some patients with severe hyperparathyroidism may be
refractory to cinacalcet treatment and therefore still need to
be referred for surgery. In the post-hoc study by Cunningham
et al.,46 the PTX rate in the cinacalcet-treated patients was 0.3
per 100 subject years versus 4.1 per 100 subject years in those
receiving standard therapy (relative risk 0.07, CI 0.01–0.55).
COST–UTITLITY
Besides efficacy, the budgetary impact of a therapeutic
measure has also to be considered, as health-care resources
are under continuous pressure. It has been calculated that the
overall use of cinacalcet in the United States will increase
the overall cost of health care by $300 million/year.159 The
additional cost per month per patient is estimated to vary
from about $300 (30 mg) to $ 1800 (180 mg).23,160 The
cost–utility of cinacalcet in addition to standard therapy
compared to standard care alone has recently been investi-
gated by Garside et al.161 These authors concluded that
according to directives from the UK National Institute for
Health and Clinical Excellence (NICE), cinacalcet––at its
current costs––cannot be considered a cost-effective treatment
for people with SHPT.161 Narayan et al.162 compared the
cost–utility of parathyroidectomy versus cinacalcet in patients
with CKD stage 5D. For patients with uncontrolled
hyperparathyroidism who are good candidates for either
drug therapy or surgery, cinacalcet is the most cost-effective
modality if the patient is to remain on dialysis therapy for
p7.25±0.25 months. Cinacalcet may be more optimal if
used in patients who have high risk of mortality or who
would expect to receive a kidney transplant quickly. For other
subgroups, parathyroidectomy is more cost-effective. These
authors assumed no rebound of the parathyroid function
after cessation of the calcimimetic at the time of transplanta-
tion. This assumption is questioned by recent clinical
evidence.113
CONCLUSION
Secondary HPT remains an important complication in
patients with CKD. It may compromise bone health and
contribute to the increased cardiovascular risks of these
patients. The treatment options of SHPT have expanded
substantially in recent years, with calcimimetic agents being
the most recent acquisition. Several strengths, weaknesses,
opportunities, and threats of calcimimetic treatment can be
discerned (Figure 1). Undoubtedly, calcimimetics may help
to achieve the stringent mineral metabolism targets in
patients with CKD stage 5D. It should however be of note
that these targets are largely opinion based. Much controversy
remains on what is the optimal PTH level in CKD stage 5D.
The correlation between PTH levels and bone turnover is
generally acknowledged to be weak. Target levels may
furthermore differ depending on the end organ (bone, heart,
vascular tree). It therefore remains to be awaited whether the
improved achievement of current mineral metabolism targets
by calcimimetic treatment will translate into improved bone
health and cardiovascular morbidity and mortality. Current
evidence, though indirect, is encouraging, but––as always––
the proof of the pudding will be in the eating.
The rationale for using calcimimetics in CKD patients not
yet on dialysis is less clear. In these patients, therapy for
SHPT should rather be focused on the primary trigger, that
is, the high phosphate load relative to the functional nephron
mass.
In patients with persistent HPT after successful renal
transplantation, therapy with calcimimetics may be useful.
Calcimimetics may help to improve bone health both by
suppressing bone turnover and demineralization and may
retard or prevent nephrocalcinosis of the graft. Further
clinical studies are urgently needed to test these hypotheses.
Additional investigations are required to define how
calcimimetics fit best in the expanding armamentarium to
treat SHPT (diet, calcium-containing and calcium-free
phosphate binders, naı¨ve and active vitamin D analogs,
parathyroidectomy).163 Given the many pleiotropic effects of
vitamin D and considering recent epidemiological data,164–170
one should beware of completely substituting vitamin D
(analogs) for calcimimetics. Combining these two drugs may
proof to be advantageous to the patients. Evidently, also the
role of PTX needs to be reevaluated in the calcimimetic era.
The lower incidence of iatrogenic hypoparathyroidism
associated with the use of cinacalcet in comparison with
Improved achievement of 
NKF-DOQI targets for mineral 
metabolism
Cost-utility
Rebound of hyperparathyroidism   
after cessation of the drug
Risks of hypocalcemia 
Gastrointestinal side effects 
Improvement in 
cardiovascular outcomes
Improvement in bone health
Attenuation of progression of











Figure 1 | SWOT analysis of calcimimetic agents.
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parathyroidectomy might be considered an advantage of the
calcimimetics. However, lacking studies comparing outcomes
of cinacalcet plus standard therapy versus parathyroidectomy,
both approaches should be considered complementary rather
than competitive. Indeed, therapy with calcimimetics may be
the only option in high-risk patients and those patients who
are unwilling to undergo surgery. On the other hand, some
patients with severe hyperparathyroidism may be refractory
to calcimimetic treatment and therefore still need to be
referred for surgery. Finally, in an era of health-care resources
being under continuous pressure, cost–utility is a major issue.
Taken together, calcimimetic agents compliment, rather than
replace, current treatment options for SHPT.
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